Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005304 | 0.83 | HTR2A (0.38) | HTR2ASHMT2KMT2A | |
| SCHEMBL7536943 | 0.79 | HTT (0.35) | TSHRKMT2A | |
| SCHEMBL7010048 | 0.75 | SHMT2 (0.42) | SHMT2KMT2AKDM4E | |
| SCHEMBL7012962 | 0.65 | MEN1 (0.39) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL7010832 | 0.64 | HPGD (0.43) | ALDH1A1TSHRKMT2AKDM4E | |
| SCHEMBL7005301 | 0.61 | HDAC1 (0.41) | KMT2A | |
| SCHEMBL12783918 | 0.61 | PLK1 (0.37) | — | |
| SCHEMBL4474987 | 0.61 | HTR2A (0.53) | HTR2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1104878 | 0.61 | GRIN2D (0.52) | HTR2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL26571880 | 0.60 | GRIN2D (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003529532-A | — | — | 2003-10-07 | — | — | JP | claimed |
| US-20020177613-A1 | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-28 | — | — | US | claimed |
| US-6376555-B1 | MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-23 | — | — | US | claimed |
| EP-1135365-A1 | 4-3-SUBSTITUTED-AMINO-CYCLOBUT-3-ENE-1,2-DIONES AND USE FOR INFLUENCING SMOOTH MUSCLE CONTRACTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2000034230-A1 | 4-3-SUBSTITUTED-AMINO-CYCLOBUT-3-ENE-1,2-DIONES AND USE FOR INFLUENCING SMOOTH MUSCLE CONTRACTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | claimed |
| US-20020177613-A1 | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-28 | — | — | US | disclosed |
| US-6465523-B1 | TREATMENT OF SMOOTH MUSCLE CONTRACTION DISORDERS SUCH AS URINARY INCONTINENCE, ASTHMA, PREMATURE LABOR, IRRITABLE BOWEL SYNDROME, CONGESTIVE HEART FAILURE, ANGINA, CEREBRAL VASCULAR DISEASE | AMERICAN HOME PRODUCTS | 2002-10-15 | — | — | US | disclosed |
| US-6462059-B1 | TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION; URINARY INCONTINENCE, ASTHMA, PREMATURE LABOR, IRRITABLE BOWEL SYNDROME, CONGESTIVE HEART FAILURE, ANGINA, AND CEREBRAL VASCULAR DISEASE | AMERICAN HOME PRODUCTS | 2002-10-08 | — | — | US | disclosed |
| US-6376555-B1 | MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177613-A1 | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | KCNN3, KCNJ2, KCNE1 | HTR2A 1845/4885SHMT2 3483/4885GRIN2D 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.